| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.689808 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107134454 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 150407s2007 onca ob f000 0 eng d |
|---|
| 020 | |a9780662458883 |
|---|
| 020 | |z9780662698272|q(incorrect) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH79-1/2007E-PDF|zH79-1/2007 |
|---|
| 245 | 00|aBudget impact analysis guidelines : |hguidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. |
|---|
| 246 | 30|aGuidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada |
|---|
| 250 | |a[First edition]. |
|---|
| 264 | 1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c2007. |
|---|
| 300 | |a1 online resource (i, 58 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Lignes directrices pour l'analyse de l'incidence du prix d'un médicament : lignes directrices pour l'analyse de l'incidence du prix d'un médicament sur les budgets des régimes d'assurance-médicaments. |
|---|
| 500 | |a"Published May 2007." |
|---|
| 504 | |aIncludes bibliographical references (pages 56-58). |
|---|
| 590 | |a10-03-Supp|b2010-06-21 |
|---|
| 650 | 0|aDrugs|xPrices|zCanada. |
|---|
| 650 | 0|aDrugs|xEconomic aspects|zCanada. |
|---|
| 650 | 0|aPharmaceutical services insurance|zCanada. |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board. |
|---|
| 775 | 08|tLignes directrices pour l'analyse de l'incidence du prix d'un médicament : |w(CaOODSP)9.634205 |
|---|
| 794 | |tBudget impact analysis guidelines : |w(CaOODSP)9.885893 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s621 KB|uhttps://publications.gc.ca/collections/collection_2008/hc-sc/H79-1-2007E.pdf |
|---|